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Abstract Enterovirus (EV) and human parechovirus (HPeV)
are major causes of sepsis-like illness in infants under 90 days
of age and have been identified as neurotropic. Studies about
acute and long-term neurodevelopment in infants with sepsis-
like illness without the need for intensive care are few. This
study investigates cerebral imaging and neurodevelopmental
outcome following EV and HPeV infection in these infants.
We studied infants under 90 days of age who were admitted to
a medium care unit with proven EV- or HPeV-induced sepsis-
like illness. In addition to standard care, we did a cerebral
ultrasound and cerebral magnetic resonance imaging (MRI),
as well as neurodevelopmental follow-up at 6 weeks and
6 months and Bayley Scale of Infant and Toddler
Development 3rd edition (BSID-III) investigation at 1 year
of age. Twenty-six infants, 22 with EVand 4 with HPeV, were
analysed. No abnormalities were detected at cerebral imaging.
At 1 year of age, two infants had a moderate delay on both the
motor and cognitive scale, one on the cognitive scale only and
three others on the gross motor scale only.
Conclusion: Although our study population, especially the
number of HPeV positive infants is small, our study shows that
these infants do not seem to develop severe neurodevelopmental
delay and neurologic sequelaemore often than the normal Dutch
population. Follow-up to school age allows for more reliable
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assessments of developmental outcome and is recommended for
further studies to better assess outcome.
What is known:
• Enterovirus and Human Parechovirus infections are a major cause of
sepsis-like illness in young infants.
• After intensive care treatment for EVor HPeV infection, white matter
abnormalities and neurodevelopmental delay have been described.
What is new:
• In our ‘medium care’ population, no abnormalities at cerebral imaging
after EV- or HPeV-induced sepsis-like illness have been found.
• At 1 year of age, infants who had EV- or HPeV-induced sepsis-like
illness do not seem to develop severe neurodevelopmental delay and
neurologic sequelae more often than the normal population.
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Introduction
Approximately half of all infants younger than 90 days of age
that are hospitalized with sepsis-like illness have an infection
with enterovirus (EV) and human parechovirus (HPeV) [1–5].
Both EVandHPeV have been identified as neurotropic viruses.
Several studies, performed at paediatric or neonatal intensive
care units (PICU/NICU), describe cerebral white matter abnor-
malities in infants with severe EV and HPeV infection.
Moreover, long-term impairment, such as neurodevelopmental
delay, cerebral palsy and epilepsy, have been reported in survi-
vors after NICU admittance for EVor HPeV infection [6, 7].
However, most infants diagnosed with EV- or HPeV-
induced sepsis-like illness do not need intensive care treat-
ment. In this less severely affected population, only two stud-
ies, both over 20 years old, about neurodevelopmental follow-
up and occurrence of neurologic sequelae exist [8, 9].
The aim of this study was to investigate cerebral imaging
and neurodevelopment up to 1 year after infection in infants
who had EV- or HPeV-induced sepsis-like illness during their
first 90 days after birth.
Materials and methods
This prospective cohort study was performed at the Juliana
Children’s Hospital, The Hague, Netherlands. Patients were
included in the study from July 2011 until October 2012, after
written informed consent from parents. The study was ap-
proved of by the regional medical ethics committee (METC
Southwest Holland, ref. 10–158).
We included infants under 90 days of age who were admit-
ted to our medium care unit with proven EV- or HPeV-induced
sepsis-like illness. The definition of sepsis-like illness was
based on age-specific criteria (Table 1). A positive diagnosis
for EVor HPeVinfection wasmade from a positive polymerase
chain reaction (PCR) result on either plasma or cerebrospinal
fluid (CSF) or both. PCRwas performed as reported earlier [5].
Exclusion criteria were congenital anomalies (including cere-
bral malformations), known or suspected immunologic disor-
ders and previous infection with EVor HPeV.
Baseline patient characteristics at admission were recorded
after inclusion. As part of the standard sepsis work-up, all
infants underwent blood and (if lumbar puncture was success-
ful) CSF sampling for biochemical analysis, viral analysis for
EV and HPeV and bacterial cultures. Herpes simplex virus
PCR was performed only on CSF.
Study protocol
Figure 1 shows the flowchart of the study protocol. One to
2 days after admission, neonatal cranial ultrasound (cUS)
views were obtained using a 7.5–10-MHz transducer [10].
Evaluation of cUS was performed using the following criteria:
inhomogeneity and/or diffuse echogenicity of the white mat-
ter, cystic abnormalities, haemorrhages and echogenicity in
the basal ganglia.
Four to 6 weeks after hospital discharge, the infants
returned to our outpatient clinic for their first follow-up visit
(t1) during which physical and neurological examinations,
cerebral magnetic resonance imaging (cMRI) and hearing
screening were done. Physical and neurologic examinations
were performed by two trained paediatric residents who were
unaware of the diagnosis of the patient.
cMRI images were obtained using a Philips 1.0 Tesla scan-
ner (GYROSCAN T10NT PT3000) with 5-mm coupes.
Sagittal T1, transversal T1, T2 dual, T2 flair and diffusion-
weighted images were obtained. Criteria for abnormalities were
as follows: white matter abnormalities (defined as diffuse high
signal intensity in the white matter on T2-weighted images and/
or punctate white matter lesions), cystic white matter lesions,
petechial haemorrhages and signs of white matter atrophy.
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During cMRI, no sedation was administered. Infants were
fed immediately prior to theMRI, after whichmost infants fell
asleep and were placed on a cushion for minimal movement.
All MR-images were reviewed by a paediatric radiologist
(HH) and neonatologist (SS), who were unaware of the clin-
ical condition or diagnosis of the patient.
Standard hearing screening was performed during the sec-
ond or third week of life by means of otoacoustic emission
[11], as part of a national newborn screening program. If chil-
dren were not screened after hospital discharge, we performed
automated auditory brain stem response hearing screening
during their first follow-up visit.
The second follow-up visit was scheduled at the age of
6 months (t = 2) to perform a full physical and neurologic
examinations and to complete a checklist for developmen-
tal milestones.
At the third follow-up visit at 1 year of age (t = 3), the
examinations performed at 6 months of age were repeated
and the Bayley Scales of Infant and Toddler Development
3rd edition (BSID-III), cognitive and motor scales were
investigated, performed by two certified paediatric physio-
therapists who were unaware of the diagnosis of the pa-
tient. We defined moderate delay as BSID-III cognitive or
motor scale scores < − 1 to – 2 SDS, and severe delay as
scale scores < − 2 SDS [12, 13].
Statistics
SPSS was used for data management (PASW statistics version
17.0) and statistical analysis (IBM SPSS statistics version
23.0). Data were checked for normality before analysis, using
descriptive statistics and histograms with z-scores for skew-
ness and kurtosis. Categorical data are shown as absolute
number/total (percentage) and numerical data as median (in-
terquartile range).
P values < 0.05 were considered to indicate statistical sig-
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Fig. 1 Study protocol and
numbers of evaluated patients.
Numbers between brackets
indicate absolute number of
patients
Table 1 Criteria for sepsis-like
illness 0–28 days 29–90 days
Clinical signs and symptoms One or more:
-Toxic appearance
-Temperature < 36.0 °C





-Capillary refill > 2 s
One or more:
-Toxic appearance
-Temperature < 36.0 °C
or > 39.0 °C
-Fever > 48 h
-Lethargy or irritability
-Capillary refill > 2 s
-Bulging fontanel
Criteria for toxic appearance Rochester criteria Yale observation scale > 10
These criteria are a local adaptation of the national guidelines for management of children with fever without
source (Dutch association of Paediatrics, NvK)
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were used for numerical data and Fisher’s exact tests for cat-
egorical data.
Results
During the study period, 34 infants met the inclusion criteria,
while none fulfilled the exclusion criteria. In eight cases, the
parents did not give informed consent for the study. We in-
cluded 26 infants (22 with EVand 4 with HPeV) in our study.
Of the 22 EV positive infants, 10 had a positive PCR in plas-
ma only, in 6/10 cases no or not enough CSF was obtained.
EV PCR was positive in CSF only in three cases. In nine, both
plasma and CSF were positive. Of the four HPeV infants, two
had positive PCR in plasma only due to failure to obtain CSF;
the remaining two had positive PCR in both plasma and CSF.
Basic patient characteristics are shown in Table 2. All in-
fants were born at term and had a normal birth weight and
normal Apgar scores. None were previously admitted to a
hospital ward with perinatal infection. All infants presented
to the paediatric emergency room with two or more signs of
sepsis-like illness. None of the infants presented with seizures
or had abnormal signs at neurologic examination at admission
or during their hospital stay.
The results of the study investigations are shown in
Tables 3 and 4. CSF pleocytosis was found in 8/17 (47%)
infants with EV infection and in none of the HPeV positive
infants. None of the patients had abnormal findings at cUS.
At the first follow-up visit 4–6 weeks after infection, 22/26
(85%) infants were evaluated. All had normal findings at
physical examination and hearing tests. Neurologic examina-
tion was abnormal in one case (1/22, 5%) showing slight
hypertonia of the lower extremities (case #1, Table 4). In this
infant, hypertonia had recovered completely at subsequent
follow-up visits. Cerebral MRI was successfully performed
in 19/26 (73%) of infants and showed no abnormal findings.
At 6 months of age, 18/26 (69%) infants were re-examined.
One infant (case #2, Table 4) had general hypotonia and slip-
ping through, but milestones were normal. In this infant, hy-
potonia had recovered at 12 months of age, but on both the
BSID-III cognitive and motor scales, this infant had moderate
developmental delay.
At 12 months of age, 20/26 (77%) infants were assessed with
the BSID-III. Two of them had experienced an HPeV infection
and 18 had an EV infection. The remaining six infants were lost
to follow-up, two because of moving of the family and four for
unknown reason. One infant had a severe delay on the gross
motor scale (case #8, Table 4), the other tested domains were
normal. Two had a moderate delay on both the motor and cog-
nitive scale (cases #2–3, Table 4), one on the cognitive scale
only (case #4, Table 4) and the others on the gross motor scale
only (cases #5–7, Table 4). None of these infants had abnormal-
ities on cerebral imaging. All infants that had a delay at BSID-III
testing were thereafter treated with physiotherapy.
Discussion
This study reports on cerebral imaging and neurodevelopmental
outcome of young infants with EV- or HPeV-induced sepsis-like
Table 2 Basic patient characteristics
Total study





Age at presentation (days) 24 (10–45) 27 (14–49) 10 (8–29)
Duration of symptoms (h) 12 (12–24) 15 (12–24) 12 (9–18)
Feeding problems 15/26 (58%) 14/22 (64%) 1/4 (25%)
Heart frequency (beats/min) 170 (158–180) 169 (155–180) 180 (171–207)
Temperature (°C) 38.6 (38.1–38.9) 38.6 (38.1–39.1) 38.3 (38.0–38.7)
Prolonged capillary refill (> 2 s) 6/26 (23%) 5/22 (23%) 1/4 (25%)
Behavioural symptoms 26/26 (100%) 22/22 (100%) 4/4 (100%)
Lethargy 4/26 (15%) 3/22 (14%) 1/4 (25%)
Irritability 22/26 (85%) 19/22 (86%) 3/4 (75%)
White blood cell count (×109/L) 6.9 (5.5–7.9) 7.5 (5.7–8.6) 5.6 (5.1–5.8)
Thrombocyte count (×109/L) 336 (254–396) 328 (268–395) 356 (197–464)
Haemoglobin (mmol/L) 8.3 (6.5–10.3) 8.2 (6.4–10.2) 8.9 (7.2–10.5)
Glucose (mmol/L) 5.2 (4.9–5.6) 5.2 (4.8–5.6) 5.2 (4.9–5.5)
C-reactive protein (mg/L) 3 (1–6) 3 (1–10) 3 (1–5)
Data are shown as absolute number/total (percentage) or as median (interquartile range). No statistically significant differences were found between EV
and HPeV positive infants
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illness in their first 90 days of life, who did not need paediatric or
neonatal intensive care admission. We investigated the presence
of neurologic signs and symptoms at three time points after EV-
or HPeV-induced sepsis-like illness during the first year of life.
In this relatively small study, one infant had a severe grossmotor
neurodevelopmental delay at 1 year of age. Two infants had a
moderate delay on both the gross motor and cognitive scales,
one on the cognitive scale only and three others on the gross
motor scale only. Two infants had transient mild abnormalities at
neurologic examination.
Neurodevelopment after EVinfection has been reported pre-
viously, but only two studies investigated this after EV sepsis/
meningitis in the first 90 days of life. Baker et al. describe
subtle deficits in receptive language processing, but no differ-
ences inmotor or cognitive development in their study group of
16 infants compared to healthy matched controls during a 3-
year follow-up period [8]. In 1981, a case control study includ-
ing nine children after EV meningitis also reported deficits in
receptive language functioning compared to nine healthy
matched controls. No differences in head circumference,
sensorineural hearing loss or intellectual functioning between
groups were found [9]. Our population was too young to in-
vestigate language development reliably. However, none of the
children required speech-language therapy. Comparing our re-
sults with these studies is difficult, since different (versions of)
developmental tests were used 20 years ago.
Only a few studies reported on the neurodevelopmental out-
come following HPeVinfection. One Australian study describes
of nine young infants with a median age at diagnosis of 13 days
requiring intensive care treatment for HPeV encephalitis and
reports ‘significant or some developmental concern’ in 7/9
(78%) of them 1 year after infection, two were diagnosed with
cerebral palsy and one with visual impairment. All had scores
below the cut-off of < 2 SD below the population mean in the
gross motor subscale of the Ages and Stages questionnaire [14].
This study shows more severe sequelae than our study does,
which can be expected from this more ill population.
Our study was performed before a Dutch normation for the
BSID-III was available; therefore, we used the USA
normation. One recent study showed that the USA normation







Hospital admission (n = 26):
Neurologic examination 0/26 0/22 0/4
CSF pleocytosisa 8/20 (40%) 8/17 (47%) 0/3
Cerebral ultrasound 0/20 0/17 0/3
t = 1: 4–6 weeks FU visit (n = 22):
Neurologic examination 1/22 (5%) 1/19b (5%) 0/3
Cerebral MRI (cMRI) 0/19 0/16 0/3
Hearing screening 0/22 0/19 0/3
t = 2: 6 m FU visit (n = 18):
Neurologic examination
(incl. milestones)
1/18 (6%) 1/16 c (6%) 0/2





Cognitive scale 3/20 (15%) e 2/18 (11%) 1/2 (50%)
Fine motor scale 0/20 0/18 0/2
Gross motor scale 6/20 (30%) f 6/18 (33%) 0/2
Numbers indicate: number of infants with abnormalities / total number of infants tested (percentage)
No statistically significant differences were found between EVand HPeV positive infants
aWe corrected CSF white blood cell count (WBC) for traumatic puncture if the CSF red blood cell count was >1000 cells/μL, using a 1000:1 ratio [17].
CSF pleocytosis was defined after correction for traumatic puncture as a CSFWBC > 19 cells/μL for children <28 days of age, >9 cells/μL for children
28–58 days of age and >5 cell/μL for children 59–90 days of age [18, 19]
b Slight hypertonia of the lower extremities (recovered at subsequent follow-up visits)
c Generalized hypotonia with slipping through (recovered at the age of one year)
d BSID interpretation: <2 SD = scaled score < 4 (severe delay), −1 to −2 SD = scaled score 4–7 (moderate delay)
e Two infants with moderate cognitive delay also had moderate gross motor delay (Table 4)
f 5/6 infants had a scaled score of 4–7, one had <4
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overestimates cognitive and fine motor development in Dutch
healthy infants, but significantly underestimates the gross mo-
tor development. This leads to a much higher percentage of
infants with low gross motor scores; 43% of Dutch infants
scored < 1 SD and 15% < 2 SD [12]. Therefore, in our
cohort, no major difference in neurodevelopmental delay
compared to healthy Dutch children of the same age was
detected [12].
We found no abnormalities on cUS during admission and
on cMRI 4 to 6 weeks after the infection. A retrospective
Norwegian study described neurodevelopmental outcome
and cerebral imaging in 15 HPeV positive infants. They were
admitted to a level 2 or 3 hospital ward. In three cases, a cMRI
was obtained showing signs of white matter necrosis in two of
them. One infant recovered completely within 8 days; the
other had normal neurodevelopment at 1 year of age [15].
Two studies describe cerebral imaging in detail in NICU-
admitted infants with HPeVinfection. One study reports white
matter damage and severe periventricular echogenicity in 9
out of 10 infants, resulting to severe neurodevelopmental de-
lay in 2 infants and minor deficits in 2 others. Two of these
infants were also born extremely premature and although cUS
abnormalities developed after infection with HPeV, these
might not be the only cause of cerebral damage [7]. Another
study describes normal sequential cUS imaging in 11 HPeV
positive infants admitted to a NICU [16].
Cerebral imaging data of EV positive infants is only available
from (neonatal) intensive care studies. In 2006, Verboon et al.
reported six infants, five infants had periventricular echogenicity
on cUS and cMRI showed diffuse high signal intensity in the
white matter, punctate white matter lesions or cystic
leucomalacia in all of them. Two infants developed cerebral
palsy and epilepsy, one was suspect for neurodevelopmental
delay at 18 months of age and three developed normally [6].
A major difference with previous studies is that we did not
investigate a NICU population and none of the infants in our
study developed seizures. Our patients were somewhat older
(up to 90 days of age at admission) and less ill than the NICU
population. Possibly, the younger and more severely ill infants
with haemodynamic instability and/or prolonged seizures,
needing intensive care treatment, are at higher risk for devel-
opment of neurologic sequelae.
Our study has its limitations, including the relatively small
cohort and missing values. Although previous studies includ-
ed cohorts of similar size, the number of patients is too still
small to allow firm conclusions, especially in terms of HPeV
infection (n = 4, at 1 year of age n = 2). We followed our study
population only for 1 year and therefore it is possible that
some neurodevelopmental problems may appear later in life
or will spontaneously resolve as children develop. Our data
must therefore be interpreted with caution and longer follow-
up studies are necessary. Follow-up to school age allows for
more reliable assessments of developmental outcome.
We did not perform typing of EVand HPeV, as this has no
consequences for treatment. Nevertheless, it would be inter-
esting to define if the more pathogenic EVor HPeV serotypes
[1, 3, 4] were present in our population. This might affect
treatment if IVIG is used and might allow for more targeted
follow-up of these specific infants.
Finally, MRI scanning was not performed during the acute
stage of the illness but 4–6 weeks after the infection.
Therefore, we may have missed possible abnormalities on
the diffusion-weighted images that disappear after the acute
phase and were only able to look for subacute signs of white
matter injury such as cystic white matter lesions, focal/
punctate white matter lesions, delayed myelination, dilatation
of the lateral ventricles and other signs of white matter volume
loss and did not find any of these white matter abnormalities in
our population. Of note, the MRI sequences used in this study
had a scan thickness of 5 mm and therefore we may have
missed some of the more subtle lesions.
Young infants with sepsis-like illness are regularly admit-
ted to paediatric wards, especially during the EV and HPeV
epidemic season in late spring and summer. We show data
from cerebral imaging in a large proportion of our study pop-
ulation (19/26). Further, negative hearing screening tests and
results from our systematic physical and neurologic examina-
tions are valuable information for paediatricians.
Our study shows that these infants do not seem to develop
neurodevelopmental delay and neurologic sequelae more often
than the normal population after a 1-year follow-up period. But,
considering our studies’ limitations, larger and longer follow-
up studies are needed to provide a more definite advice.
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